Document is current
Any future updates will be listed below
-
Authors
Mehr, Pouya E.
Ortiz, Pedro J.
O’Rourke, Kaitlyn R.
Ding, Tan
Hackstadt, Amber J.
Kulapatana, Surat
Diedrich, André
Claassen, Daniel O.
Biaggioni, Italo
Peltier, Amanda C.
Shibao, Cyndya A. https://orcid.org/0000-0002-4518-6801
-
Funding
Funding for this research was provided by:
NIH (R01HL159203)
NIH (K24HL165163)
NIH (R01HL161095)
NIH (R01HL144568)
NIH (U01NS122419)
NIH (UL1TR000445)
Overton and Jeanette Smith Foundation
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 26 April 2025
First Online: 13 May 2025
Declarations
:
: IB and CAS are consultants for Theravance Biopharma. CAS is a member of the scientific board for Antag Therapeutics. Other authors have no conflict of interest.
